awmsg logo

certolizumab pegol (Cimzia®)

Reference No. 1211

Publication date:

Appraisal information

certolizumab pegol (Cimzia®) 200 mg solution for injection

Company: UCB Pharma Ltd
BNF category: Musculoskeletal and joint diseases
NMG meeting date: 10/09/2014
AWMSG meeting date: 08/10/2014
Submission Type: Full Submission
Status: Superseded
Advice No: 3114
Ratification by Welsh Government: 30/10/2014

Current Progress

Ratification by
Welsh Government

AWMSG advice

AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE (TA383) NICE GUIDANCE ISSUED FEBRUARY 2016 (Refer to NICE website for full guidance on NICE recommendations, including any specific restrictions on the use of the technology) Certolizumab pegol (Cimzia®) is recommended as an option for use within NHS Wales for the treatment of adult patients with severe active axial spondyloarthritis, comprising: adults with severe active ankylosing spondylitis (AS) who have had an inadequate response to, or are intolerant to nonsteroidal anti-inflammatory drugs (NSAIDs); and adults with severe active axial spondyloarthritis without radiographic evidence of AS but with objective signs of inflammation by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI), who have had an inadequate response to, or are intolerant to NSAIDs. This recommendation applies only in circumstances where the approved Wales Patient Access Scheme is utilised.
Final Appraisal Recommendation (FAR)
AWMSG Secretariat Appraisal Report (ASAR)
Clinical Expert (CE) Summary